您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 泌尿生殖系统及泌乳药物->前列腺疾病用药
处方药:处方药
包装规格: 20毫克/片 60片/瓶
计价单位:
   
生产厂家中文参考译名:
礼来
生产厂家英文名:
ELI LILLY CO
该药品相关信息网址1:
http://www.igenericdrugs.com/gd.cgi?notran=1&s=Adcirca&search=SEARCH
原产地英文商品名:
Adcirca 20mg 60 Tablets
原产地英文药品名:
Pramipexole
中文参考商品译名:
Adcirca 20毫克/片 60片/瓶
中文参考药品译名:
他达拉非
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
erectile dysfunction (impotence)
英文适应病症2:
symptoms of benign prostatic hypertrophy (enlarged prostate)
临床试验期:
完成
中文适应病症参考翻译1:
勃起机能障碍(阳痿)
中文适应病症参考翻译2:
良性前列腺肥大(前列腺肥大)的症状
药品信息:

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201411514553723.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Adcirca 2处方资料(仅供参考)

美国食品药品管理局(FDA)已经批准他达拉非(Adcirca)用于治疗肺动脉高压(PAH)。他达拉非是一种磷酸二脂酶5(PDE5)抑制剂。PAH已归入世界卫生组织(WHO)I类疾病中,根据病因学可分为多种类型,诸如先天性和家族性PAH,以及硬皮病相关性PAH和先天性心脏病相关性PAH。他达拉非适用于改善上述PAH患者的运动能力。

在一项历时16周、随机、双盲、安慰剂对照、III期临床试验中,为了探讨他达拉非对PAH的疗效,试验组患者服用他达拉非,每日1次,剂量为40mg(20mg片剂2片);与安慰剂对照组患者相比,试验组患者6min行走距离提高了33m。此外,服用40mg 他达拉非的试验组患者临床病情恶化次数亦少于安慰剂对照组。试验中最常见的不良事件基本上为暂时性,在严重程度上可视为轻度至中度, 其中包括头痛、面部潮红、鼻咽炎、肌肉疼痛、腹部不适、鼻塞、呼吸道感染,以及双臂、双下肢或背部的疼痛。

他达拉非等PDE5抑制剂有轻度的全身性扩血管效应,可导致血压一过性下降。因此,对于有潜在的心血管疾病的患者,医生在开他达拉非处方前,应慎重考虑患者是否会因这种效应而受到不利影响。在患有肺静脉闭塞症的患者,应用肺血管扩张剂可能会使其心血管状态明显恶化,故这类患者不适宜应用他达拉非。此外,鉴于该药与硝酸盐类药物联用可能会导致血压骤然、不安全地下降,所以也不适用于服用硝酸盐类药物的患者。

某些服用PDE5抑制剂(包括他达拉非)的患者中有极少数报告了视力或听力突然下降或丧失,而某些服用该药的男性勃起曾长达4h以上。医生应告知患者,若其出现上述任何不良反应,要立即去就诊。

Adcirca - Adcirca relaxes muscles and increases blood flow to particular areas of the body. Adcirca under the name of Cialis is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate). Another brand of sildenafil is Adcirca, which is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women.

Adcirca may also be used for purposes not listed in this medication guide. Used for: Treating high blood pressure in the lungs (pulmonary arterial hypertension [PAH]. It may also be used for other conditions as determined by your doctor.

AAdcirca is a phosphodiesterase type 5 (PDE5) inhibitor. It works by relaxing and dilating the vessels in the lungs. This lowers the blood pressure in the lungs and helps to improve your ability to exercise.

AAdcirca is a medication for the treatment of erectile dysfunction. This drug is a selective inhibitor of PDE5-specific cGMP. When sexual stimulation causes local release of nitric oxide, inhibition of PDE5 Adcirca leads to increased levels of cGMP in the cavernous body of penis. The result is relaxation of smooth muscles of arteries and blood flow to the tissues of the penis, causing erection. Adcirca is ineffective in the absence of sexual stimulation.

Studies in vitro have shown that Adcirca is a selective inhibitor of PDE5. PDE5 is an enzyme found in smooth muscles of cavernous bodies in vascular smooth muscle of the internal organs, skeletal muscle, platelets, kidney, lung cerebellum.

A Effect of Adcirca on PDE5 is more active than other phosphodiesterase. Adcirca in 10,000 times more potent for PDE5 than for FDE1, FDE2, PDE4, which are located in the heart, brain, blood vessels, liver and other organs. This medication in 10,000 times more active blocks PDE5 than FDE3 - an enzyme that is found in the heart and blood vessels. This selectivity for PDE5 compared with FDE3 is important because FDE3 is an enzyme participating in the reduction of the heart muscle. In addition, Adcirca is about 700 times more potent for PDE5 than for FDE6, found in the retina and is responsible for photo transfer.

Adcirca acts within 36 hours. The effect is already apparent 16 minutes after ingestion in the presence of sexual arousal.

Adcirca in healthy individuals does not cause significant changes in systolic and diastolic blood pressure compared with placebo in the prone position (mean maximum decrease of 1.6/0.8 mm Hg, respectively) and standing (mean maximum decrease of 0.2/4.6 mm Hg, respectively). Adcirca does not cause significant changes in heart rate. This medicine does not cause changes in the recognition of colors (blue / green), due to its low affinity for PDE6. In addition, no marked effect of Adcirca on visual acuity, electroretinogram, intraocular pressure and pupil size.

Clinically significant effect on the characteristics of sperm in men taking Adcirca in daily doses for 6 months has not been identified.

Adcirca is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease. Active ingredients: Tadalafil

更新日期: 2013-07-27
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com